Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 CNS-active medications per resident at baseline and follow-up

From: Engagement is a necessary condition to test audit and feedback design features: results of a pragmatic, factorial, cluster-randomized trial with an embedded process evaluation

CNS-active medications per resident

Trial arm 1

Median comparator & benefit framing

Trial arm 2

Top quartile comparator & benefit framing

Trial arm 3

Median comparator & risk framing

Trial arm 4

Top quartile comparator & risk framing

Baseline

n residents

2817

3277

3768

2725

Mean ± SD

1.12 ± 1.04

1.26 ± 1.10

1.07 ± 1.04

1.10 ± 1.07

At 6 months

n residents

2904

3334

3989

2744

Mean ± SD

1.13 ± 1.02

1.28 ± 1.10

1.06 ± 1.02

1.10 ± 1.07

Back to article page

Implementation Science

ISSN: 1748-5908